Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of HRS-9813 in Healthy Volunteers
NCT06514963Phase 1Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jul 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-9813 in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Incidence of Adverse Event (AE) and Serious Adverse Event (SAE) at 14 days. Started Jul 2024; status: completed.
02
Drugs
HRS-9813
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06514963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06514963.